Saniona AB (publ) (SANION.ST)
SEK 6.67
(-0.74%)
SEK 6.67
(-0.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 64.14 Million SEK | -58.27% |
| 2022 | 153.69 Million SEK | -65.09% |
| 2021 | 440.24 Million SEK | -36.4% |
| 2020 | 692.18 Million SEK | 621.02% |
| 2019 | 96 Million SEK | 15.56% |
| 2018 | 83.07 Million SEK | 71.73% |
| 2017 | 48.37 Million SEK | -31.64% |
| 2016 | 70.76 Million SEK | 22.71% |
| 2015 | 57.67 Million SEK | 273.02% |
| 2014 | 15.46 Million SEK | 2.59% |
| 2013 | 15.07 Million SEK | 87.94% |
| 2012 | 8.01 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 107.69 Million SEK | 67.9% |
| 2024 Q2 | 92.46 Million SEK | -14.15% |
| 2023 Q3 | 94.4 Million SEK | -18.65% |
| 2023 FY | 64.14 Million SEK | -58.27% |
| 2023 Q1 | 132.32 Million SEK | -13.9% |
| 2023 Q4 | 64.14 Million SEK | -32.06% |
| 2023 Q2 | 116.04 Million SEK | -12.31% |
| 2022 Q1 | 348.28 Million SEK | -20.89% |
| 2022 Q3 | 192.62 Million SEK | -20.97% |
| 2022 Q4 | 153.69 Million SEK | -20.21% |
| 2022 FY | 153.69 Million SEK | -65.09% |
| 2022 Q2 | 243.75 Million SEK | -30.02% |
| 2021 Q4 | 440.24 Million SEK | -17.58% |
| 2021 FY | 440.24 Million SEK | -36.4% |
| 2021 Q3 | 534.15 Million SEK | 0.85% |
| 2021 Q2 | 529.63 Million SEK | -15.12% |
| 2021 Q1 | 624 Million SEK | -9.85% |
| 2020 Q4 | 692.18 Million SEK | -11.95% |
| 2020 Q1 | 122.2 Million SEK | 27.3% |
| 2020 FY | 692.18 Million SEK | 621.02% |
| 2020 Q2 | 218.97 Million SEK | 79.18% |
| 2020 Q3 | 786.09 Million SEK | 258.99% |
| 2019 Q4 | 96 Million SEK | 6.26% |
| 2019 FY | 96 Million SEK | 15.56% |
| 2019 Q1 | 82.23 Million SEK | -1.01% |
| 2019 Q2 | 131.44 Million SEK | 59.84% |
| 2019 Q3 | 90.34 Million SEK | -31.27% |
| 2018 Q3 | 61.58 Million SEK | 20.58% |
| 2018 FY | 83.07 Million SEK | 71.73% |
| 2018 Q4 | 83.07 Million SEK | 34.89% |
| 2018 Q1 | 53.31 Million SEK | 10.21% |
| 2018 Q2 | 51.07 Million SEK | -4.19% |
| 2017 Q1 | 58.83 Million SEK | -16.86% |
| 2017 FY | 48.37 Million SEK | -31.64% |
| 2017 Q3 | 65.54 Million SEK | -16.46% |
| 2017 Q4 | 48.37 Million SEK | -26.19% |
| 2017 Q2 | 78.45 Million SEK | 33.35% |
| 2016 Q2 | 47.83 Million SEK | -20.03% |
| 2016 Q1 | 59.81 Million SEK | 3.71% |
| 2016 FY | 70.76 Million SEK | 22.71% |
| 2016 Q4 | 70.76 Million SEK | -14.65% |
| 2016 Q3 | 82.91 Million SEK | 73.34% |
| 2015 Q4 | 57.67 Million SEK | 118.45% |
| 2015 FY | 57.67 Million SEK | 273.02% |
| 2015 Q1 | 36.08 Million SEK | 133.37% |
| 2015 Q2 | 33.8 Million SEK | -6.31% |
| 2015 Q3 | 26.4 Million SEK | -21.9% |
| 2014 FY | 15.46 Million SEK | 2.59% |
| 2014 Q2 | 24.92 Million SEK | 0.0% |
| 2014 Q3 | 20.6 Million SEK | -17.33% |
| 2014 Q4 | 15.46 Million SEK | -24.97% |
| 2013 FY | 15.07 Million SEK | 87.94% |
| 2012 FY | 8.01 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 47.931% |
| Amniotics AB (publ) | 26.08 Million SEK | -145.891% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -955.504% |
| BioArctic AB (publ) | 1.18 Billion SEK | 94.592% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 96.625% |
| Genovis AB (publ.) | 288.85 Million SEK | 77.794% |
| LIDDS AB (publ) | 17.65 Million SEK | -263.314% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 76.989% |
| OncoZenge AB (publ) | 20.34 Million SEK | -215.354% |
| Simris Alg AB (publ) | 174.55 Million SEK | 63.253% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 87.074% |
| AcouSort AB (publ) | 34.51 Million SEK | -85.852% |
| Active Biotech AB (publ) | 44 Million SEK | -45.78% |
| Camurus AB (publ) | 1.9 Billion SEK | 96.638% |
| Cantargia AB (publ) | 223.71 Million SEK | 71.328% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -331.387% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 24.739% |
| Mendus AB (publ) | 755.95 Million SEK | 91.515% |
| Kancera AB (publ) | 65.64 Million SEK | 2.285% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 94.903% |
| Lipum AB (publ) | 12.11 Million SEK | -429.67% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -90.89% |
| NextCell Pharma AB | 81.28 Million SEK | 21.092% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 90.185% |
| Xintela AB (publ) | 18.39 Million SEK | -248.698% |
| Ziccum AB (publ) | 14.97 Million SEK | -328.42% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -112.584% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -220.059% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 54.378% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 91.618% |
| CombiGene AB (publ) | 120.61 Million SEK | 46.819% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 70.446% |
| Intervacc AB (publ) | 259.61 Million SEK | 75.293% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 45.848% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -2.831% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -52.871% |
| Corline Biomedical AB | 100.1 Million SEK | 35.924% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 63.786% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -3.203% |
| Aptahem AB (publ) | 63.02 Million SEK | -1.774% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 81.743% |
| Fluicell AB (publ) | 9.34 Million SEK | -586.756% |
| Biovica International AB (publ) | 131.4 Million SEK | 51.188% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -21.059% |
| Abliva AB (publ) | 87.49 Million SEK | 26.693% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 91.562% |
| 2cureX AB (publ) | 16.62 Million SEK | -285.823% |
| I-Tech AB | 152.44 Million SEK | 57.923% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 93.699% |
| Cyxone AB (publ) | 43.65 Million SEK | -46.932% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 18.489% |
| Biosergen AB | 7.2 Million SEK | -790.751% |
| Nanologica AB (publ) | 77.42 Million SEK | 17.159% |
| SynAct Pharma AB | 228.01 Million SEK | 71.869% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -139.67% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 95.419% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -195.551% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 73.092% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -658.64% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 26.333% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -125.0% |